This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Years of investment in digital, cloud and security strategy has helped Accenture evolve as a trusted and viable consulting services provider. It is currently the world’s top consultancy firm by revenues that increased 5% in 2019 with a contribution of 56% from consulting services.
UIS Stock Ahead of Q3 Earnings Report: To Buy or Not to Buy?
by Zacks Equity Research
Unisys' third-quarter 2024 results are expected to benefit from strong demand for Digital Workplace Solutions and Cloud-Based Solutions.
Can VRT's Q3 Earnings Beat & Raised 2024 View Push the Stock Higher?
by Zacks Equity Research
Vertiv's third-quarter 2024 results reflect strong order increase, solid organic growth and margin expansion.
Is Unisys Stock a Buy, Sell or Hold at 0.19X Price/Sales Ratio?
by Aniruddha Ganguly
UIS is an attractive stock for growth-oriented investors, given its portfolio strength and strong partner base.
Vertiv Holdings Co. (VRT) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Vertiv (VRT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Accenture (ACN) Stock Moves -0.31%: What You Should Know
by Zacks Equity Research
The latest trading day saw Accenture (ACN) settling at $370.63, representing a -0.31% change from its previous close.
Interpublic Group Earnings Meet Estimates in Q3, Revenues Miss
by Zacks Equity Research
IPG's third-quarter 2024 total revenues decline year over year. Earnings remain flat with the year-ago quarter.
3 Reasons Why Growth Investors Shouldn't Overlook Accenture (ACN)
by Zacks Equity Research
Accenture (ACN) possesses solid growth attributes, which could help it handily outperform the market.
Bitcoin on Track to Hit $70,000: 4 Crypto-Centric Stocks With Upside
by Ritujay Ghosh
Bitcoin-centric stocks like NVDA, CME, IBKR and ACN are poised to gain from the ongoing cryptocurrency rally.
The Zacks Analyst Blog Highlights AstraZeneca, Accenture, AT&T and National Presto Industries
by Zacks Equity Research
AstraZeneca, Accenture, AT&T and National Presto Industries are part of the Zacks top Analyst Blog.
Top Research Reports for AstraZeneca, Accenture & AT&T
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), Accenture plc (ACN) and AT&T Inc. (T), as well as a micro-cap stock National Presto Industries, Inc. (NPK).